Cargando…
Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease
INTRODUCTION: Dopaminergic medications can trigger impulsive-compulsive behaviors (ICBs) in pre-disposed patients with Parkinson's disease (PD), but what this implies on a neurocognitive level is unclear. Previous findings highlighted potentially exacerbated incentive motivation (willingness to...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889554/ https://www.ncbi.nlm.nih.gov/pubmed/36744102 http://dx.doi.org/10.3389/fnbeh.2022.949406 |
_version_ | 1784880758148562944 |
---|---|
author | Dawson, Andrew Ortelli, Paola Carter, Adrian Ferrazzoli, Davide Dissanayaka, Nadeeka N. Evans, Andrew Chye, Yann Lorenzetti, Valentina Frazzitta, Giuseppe Yücel, Murat |
author_facet | Dawson, Andrew Ortelli, Paola Carter, Adrian Ferrazzoli, Davide Dissanayaka, Nadeeka N. Evans, Andrew Chye, Yann Lorenzetti, Valentina Frazzitta, Giuseppe Yücel, Murat |
author_sort | Dawson, Andrew |
collection | PubMed |
description | INTRODUCTION: Dopaminergic medications can trigger impulsive-compulsive behaviors (ICBs) in pre-disposed patients with Parkinson's disease (PD), but what this implies on a neurocognitive level is unclear. Previous findings highlighted potentially exacerbated incentive motivation (willingness to work for rewards) and choice impulsivity (preferring smaller, immediate rewards over larger, delayed rewards) in PD patients with ICBs (PD + ICBs). METHODS: To deeply understand this evidence, we studied 24 PD + ICBs and 28 PD patients without ICBs (PD-ICBs). First of all, patients underwent the assessment of impulsivity traits, mood, anxiety, and addiction condition. We further administered robust objective and subjective measures of specific aspects of motivation. Finally, we explored whether these processes might link to any heightened antisocial behavior (aggression and risky driving) in PD + ICBs. RESULTS: High levels of positive urgency trait characterized PD + ICBs. They choose to exert more effort for rewards under the conditions of low and medium reward probability and as reward magnitude increases. Findings on choice impulsivity show a great tendency to delay discounting in PD + ICBs, other than a high correlation between delay and probability discounting. In addition, we found what appears to be the first evidence of heightened reactive aggression in PD patients with ICBs. Exacerbated incentive motivation and delay discounting trended toward positively predicting reactive aggression in PD + ICBs. DISCUSSION: Our promising results suggest that there might be immense value in future large-scale studies adopting a transdiagnostic neurocognitive endophenotype approach to understanding and predicting the addictive and aggressive behaviors that can arise from dopaminergic medication in PD. |
format | Online Article Text |
id | pubmed-9889554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98895542023-02-02 Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease Dawson, Andrew Ortelli, Paola Carter, Adrian Ferrazzoli, Davide Dissanayaka, Nadeeka N. Evans, Andrew Chye, Yann Lorenzetti, Valentina Frazzitta, Giuseppe Yücel, Murat Front Behav Neurosci Behavioral Neuroscience INTRODUCTION: Dopaminergic medications can trigger impulsive-compulsive behaviors (ICBs) in pre-disposed patients with Parkinson's disease (PD), but what this implies on a neurocognitive level is unclear. Previous findings highlighted potentially exacerbated incentive motivation (willingness to work for rewards) and choice impulsivity (preferring smaller, immediate rewards over larger, delayed rewards) in PD patients with ICBs (PD + ICBs). METHODS: To deeply understand this evidence, we studied 24 PD + ICBs and 28 PD patients without ICBs (PD-ICBs). First of all, patients underwent the assessment of impulsivity traits, mood, anxiety, and addiction condition. We further administered robust objective and subjective measures of specific aspects of motivation. Finally, we explored whether these processes might link to any heightened antisocial behavior (aggression and risky driving) in PD + ICBs. RESULTS: High levels of positive urgency trait characterized PD + ICBs. They choose to exert more effort for rewards under the conditions of low and medium reward probability and as reward magnitude increases. Findings on choice impulsivity show a great tendency to delay discounting in PD + ICBs, other than a high correlation between delay and probability discounting. In addition, we found what appears to be the first evidence of heightened reactive aggression in PD patients with ICBs. Exacerbated incentive motivation and delay discounting trended toward positively predicting reactive aggression in PD + ICBs. DISCUSSION: Our promising results suggest that there might be immense value in future large-scale studies adopting a transdiagnostic neurocognitive endophenotype approach to understanding and predicting the addictive and aggressive behaviors that can arise from dopaminergic medication in PD. Frontiers Media S.A. 2023-01-18 /pmc/articles/PMC9889554/ /pubmed/36744102 http://dx.doi.org/10.3389/fnbeh.2022.949406 Text en Copyright © 2023 Dawson, Ortelli, Carter, Ferrazzoli, Dissanayaka, Evans, Chye, Lorenzetti, Frazzitta and Yücel. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Behavioral Neuroscience Dawson, Andrew Ortelli, Paola Carter, Adrian Ferrazzoli, Davide Dissanayaka, Nadeeka N. Evans, Andrew Chye, Yann Lorenzetti, Valentina Frazzitta, Giuseppe Yücel, Murat Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease |
title | Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease |
title_full | Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease |
title_fullStr | Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease |
title_full_unstemmed | Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease |
title_short | Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease |
title_sort | motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in parkinson's disease |
topic | Behavioral Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889554/ https://www.ncbi.nlm.nih.gov/pubmed/36744102 http://dx.doi.org/10.3389/fnbeh.2022.949406 |
work_keys_str_mv | AT dawsonandrew motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease AT ortellipaola motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease AT carteradrian motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease AT ferrazzolidavide motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease AT dissanayakanadeekan motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease AT evansandrew motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease AT chyeyann motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease AT lorenzettivalentina motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease AT frazzittagiuseppe motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease AT yucelmurat motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease |